Please assess the completion status of the following clinical trial:

Trial Title: Using Vedolizumab-800CW to Gain Insight Into Local Drug Distribution and Mucosal Target Cells in IBD Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Established diagnosis of IBD, or Ulcerative Colitis (UC) or Crohn's Disease (CD).~* Vedolizumab naïve and eligible for vedolizumab treatment.~* Age: 18 years or older.~* Written informed consent.~Exclusion Criteria:~* Prior vedolizumab treatment~* Vedolizumab contraindicated as therapy~* Pregnancy or breast feeding.~* Patients younger than 18 years old

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No administration of vedolizumab-800CW (Type: OTHER): Patients did not receive vedolizumab-800CW but underwent a Fluorescence molecular imaging procedure to serve as a control group and compare results with patients receiving the tracer
- 4.5 mg vedolizumab-800CW group (Type: EXPERIMENTAL): Patients received 4.5 mg vedolizumab-800CW and subsequently underwent a Fluorescence molecular imaging procedure
- 15 mg vedolizumab-800CW group (Type: EXPERIMENTAL): Patients received 15 mg vedolizumab-800CW and subsequently underwent a Fluorescence molecular imaging procedure
- 75 mg vedolizumab + 15 mg vedolizumab-800CW group (Type: EXPERIMENTAL): Patients received 75mg vedolizumab + 15 mg vedolizumab-800CW and subsequently underwent a Fluorescence molecular imaging procedure
- 300mg vedolizumab + 15mg vedolizumab-800CW group (Type: EXPERIMENTAL): Patients received 300mg vedolizumab + 15 mg vedolizumab-800CW and subsequently underwent a Fluorescence molecular imaging procedure
- > 14 weeks of vedolizumab therapy + 15 mg vedolizumab-800CW group (Type: EXPERIMENTAL): Patients received 300mg vedolizumab + 15 mg vedolizumab-800CW after \>14 weeks vedolizumab therapy and subsequently underwent a Fluorescence molecular imaging procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).